Lupus NephritisPhase 3REGENCYNCT04221477
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
A Phase 3 study testing Obinutuzumab, MMF and Prednisone in people with Lupus Nephritis, run by Hoffmann-La Roche at 74 sites in 15 countries.
Trial summary
This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Lupus Nephritis
- What is being tested?
- Obinutuzumab, MMF and Prednisone
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 271 participants
- Where
- 74 sitesin 15 countries
- Study dates
- 10 Aug 2020to 2 Mar 2031
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of active or active/chronic ISN/RPS 2003 Class III or IV proliferative LN as evidenced by renal biopsy performed within 6 months. Participants may co-exhibit Class V disease in addition to either Class III or Class IV disease
- Urine protein to creatinine ratio greater than or equal to (>/=) 1 on a 24-hour collection
- Other inclusion criteria may apply
Who cannot join
- Pregnancy or breastfeeding
- Severe renal impairment or the need for dialysis or renal transplantation
- Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to screening or during screening; or cyclophosphamide, tacrolimus, ciclosporin, or voclosporin during the 2 months prior to screening or during screening
- Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
- Known active infection of any kind or recent major episode of infection
- Intolerance or contraindication to study therapies
- Other exclusion criteria may apply
Trial locations and contacts
74 sites in 15 countries.
74 sites in 15 countries
United States18 sites
Univ Colorado Health Sci Ctr
Aurora, Colorado, 80045
Wallace Rheumatic Study Center
Beverly Hills, California, 90211
University of Alabama at Birmingham Medical Center
Birmingham, Alabama, 35233
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43212
University of Texas Southwestern
Dallas, Texas, 75390-8897
Kaiser Permanente - Fontana
Fontana, California, 92335
Georgia Nephrology
Lawrenceville, Georgia, 30046
North Shore University Hospital
Manhasset, New York, 11030
Southwest Rheumatology
Mesquite, Texas, 75150
University of Miami Miller School of Medicine
Miami, Florida, 33136
Yale Medical Group
New Haven, Connecticut, 06520
NYU Langone Medical Center
New York, New York, 10016
Columbia University Medical Center
New York, New York, 10032
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
AD-CARE, University of Rochester Medical Center
Rochester, New York, 14620
University of Utah Health Science center
Salt Lake City, Utah, 84113
Kaiser Permanente - San Francisco Medical Center
San Francisco, California, 94118
Stanford University Medical Center
Stanford, California, 94305
Poland7 sites
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
Lublin, 20-954
Medyczne Centrum Hetmanska
Poznan, 60-218
Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM
Poznan, 61-545
Szpital Kliniczny Dzieciatka Jezus
Warsaw, 02-006
Rheuma Medicus Zaklad Opieki Zdrowotnej
Warsaw, 02-118
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. Prof. Eleonory Reicher
Warsaw, 02-637
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroclaw, 50-556
Germany6 sites
Charité Campus Mitte, Med.Klinik, Rheumatologie und Klinische Immunologie
Berlin, 10117
Städtisches Klinik Dresden-Friedrichstadt
Dresden, 01067
Universitätsklinikum "Carl Gustav Carus"
Dresden, 01307
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106
Universitaetsmedizin Johannes Gutenberg
Mainz, 55131
Universitätskrankenhaus Tübingen
Tübingen, 72076
Brazil5 sites
Instituto Pro-Renal
Curitiba, Paraná, 80440-020
Hospital das Clinicas - FMUSP Ribeirao Preto
Ribeirão Preto, São Paulo, 14048-900
Ser Servicos Especializados Em Reumatologia
Salvador, Estado de Bahia, 40150-150
Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*
Santo André, São Paulo, 09190-510
Hospital das Clinicas - FMUSP
São Paulo, São Paulo, 05403-000
France5 sites
Hopital Henri Mondor
Créteil, 94010
Hopital Claude Huriez
Lille, 59037
Groupe Hospitalier Pitie-Salpetriere
Paris, 75651
Hopital Bichat Claude Bernard
Paris, 75877
Hopital Rangueil
Toulouse, 31059
Italy5 sites
Policlinico di Bari
Bari, Apulia, 70124
A.O. Spedali Civili Di Brescia-P.O. Spedali Civili
Brescia, Lombardy, 25123
Azienda Ospedaliera Universitaria Careggi
Florence, Tuscany, 50141
Ospedale Policlinico San Martino
Genoa, Liguria, 16132
Azienda Ospedaliera di Padova
Padova, Veneto, 35128
Peru5 sites
Instituto Peruano del Hueso y la Articulación
Lima, 15046
Clínica San Juan Bautista CSJB
Lima, 15431
Instituto del Cerebro y la Columna Vertebral SAC
Lima, Lima 18
Instituto de Ginecología y Reproducción
Lima
Hospital Nacional Cayetano Heredia
San Martín de Porres, 15102
Israel4 sites
Meir Medical Center
Kfar Saba, 4428164
Rabin MC- Belinson campus
Petah Tikva, 49100
Chaim Sheba Medical Center
Ramat Gan, 5262000
Sourasky Medical Centre
Tel Aviv, 64239
Russia4 sites
?Kazan (Privolzhsky) Federal University?
Kazan', Tatarstan Republic, 420043
Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
Moscow, Moscow Oblast, 115522
Federal Centre of Heart, Blood and Endocrinology n.a. V.A.Almazov
Saint Petersburg, Sankt-Peterburg, 197341
SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
Saint Petersburg, 197022
Spain4 sites
Hospital Universitario Vall d'Hebron
Barcelona, 08035
Hospital Clinic i Provincial
Barcelona, 08036
Hospital Ramon y Cajal
Madrid, 28034
Hospital Universitario 12 de Octubre
Madrid, 28041
Argentina3 sites
Organizacion Medica de Investigacion
Buenos Aires, C1015ABO
DOM Centro de Reumatología
Buenos Aires, C1111AAJ
Sanatorio Allende
Córdoba, X5000JHQ
Colombia3 sites
Clinica De La Costa
Barranquilla
Hospital Universitario San Ignacio
Bogotá, 000472
Hospital Pablo Tobon Uribe
Medellín, 050034
Mexico3 sites
Centro de Investigación y Tratamiento Reumatológico S.C.
Mexico City, Mexico CITY (federal District), 11850
Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán
Mexico City, Mexico CITY (federal District), Tlalpan 14000
Hospital Universitario
Monterrey, Nuevo León, 64460
South Africa1 site
Groote Schuur Hospital and University of Cape Town
Cape Town, 7925
United Kingdom1 site
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
Cambridge, CB2 0QQ
About this study
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.
- Conditions
- Lupus Nephritis
- Being tested
- Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone
- Medical subject headings
- Lupus Nephritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObinutuzumabDrug
Also called Gazyva, GA101, RO5072759
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg at Baseline and Weeks 2, 24, 26, 50 (group 2: placebo), and 52 and subsequently from Week 80 and every 6 months thereafter, based on response.
MMFDrug
MMF willl be administered at a target dose of 2.0 - 2.5 g/day in divided doses through Week 80.
PrednisoneDrug
Prednisone 0.5 mg/kg/day (maximum 60 mg/day) will be started on Day 2. Beginning on Day 15, prednisone will be tapered to 5 mg/day and continued until Week 80.
PlaceboDrug
Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
Methylprednisolone 80 mg IV will be administered as predmedication prior to infusions.
AcetaminophenDrug
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
DiphenhydramineDrug
Diphenhydramine 50 mg will be administered as premedication prior to infusions.
| Study group | Role | What they receive |
|---|---|---|
| Obinutuzumab | Experimental | Participants will be randomized into 2 groups. Group 1 will receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone. Group 2 receive obinutuzumab 1000 mg IV at baseline and Weeks 2, 24, 26, and 52 plus MMF and oral prednisone. Group 2 participants will receive a placebo infusion at their Week 50 visit.
Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80.
After study unblinding, participants may be eligible for further open-label obinutuzumab treatment. Receives: Drug: Obinutuzumab; Drug: MMF; Drug: Prednisone; Drug: Methylprednisolone; Drug: Acetaminophen; Drug: Diphenhydramine |
| Placebo | Placebo comparator | Placebo participants will receive obinutuzumab matched placebo at baseline and Weeks 2, 24, 26, 50, and 52 plus MMF and oral prednisone.
Participants with an adequate response at Week 76 will continue receiving blinded obinutuzumab infusions every 6 months starting at Week 80.
Participants without an adequate response at Week 76 may be eligible for open-label obinutuzumab starting at Week 80.
After study unblinding, participants may be eligible for further open-label obinutuzumab treatment. Receives: Drug: Obinutuzumab; Drug: MMF; Drug: Prednisone; Drug: Placebo; Drug: Methylprednisolone; Drug: Acetaminophen; Drug: Diphenhydramine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Complete Renal Response (CRR)
CRR was defined as an achievement of all the following criteria: urinary protein-to-creatinine ratio (UPCR) <0.5 gram/gram (g/g); estimated glomerular filtration rate (eGFR) >=85% of baseline, as calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Obinutuzumab and placebo were compared using Cochran-Mantel-Haenszel (CMH) test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using fully conditional specification (FCS) predicted mean matching method. Percentage have been rounded off.
Measured: At Week 76
Secondary outcomes (16)
Percentage of Participants Who Achieve CRR With Successful Prednisone Taper at Week 76
CRR with successful prednisone was defined as the achievement of CRR at Week 76 with no receipt of prednisone >7.5 milligrams per day (mg/day) (or equivalent) from Week 64 through Week 76. CRR was defined as achievement of all the following criteria: UPCR <0.5 g/g; eGFR >=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Measured: At Week 76
Percentage of Participants Who Achieve a Proteinuric Response
Proteinuric response was defined as an achievement of all the following criteria: UPCR <0.8 g/g and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Measured: At Week 76
Mean Change in eGFR
Change in eGFR from baseline to Week 76 was analyzed using Analysis of Covariance (ANCOVA) model with covariates baseline eGFR and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. mL/min/1.73 m^2 = milliliters per minute per 1.73 square meters. Adjusted mean has been reported.
Measured: At Week 76
Percentage of Participants Who Experience Death or Renal-related Events
Percentage of participants with death or renal-related events were defined as participants with one or more of the following events: Death; Treatment failure; Worsening proteinuria, defined as a confirmed ≥50% increase in UPCR to a value ≥3 g/g; Worsening eGFR, defined as a confirmed ≥30% decrease in eGFR to a value <60. Early study withdrawal due to lack of efficacy was an intercurrent event. Participants experiencing the intercurrent event were considered as participants with events under composite strategy. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentages have been rounded off.
Measured: From Day 1 to Week 76
Percentage of Participants Who Achieve an Overall Renal Response (ORR)
ORR was defined as achievement of either CRR or PRR. CRR was defined as achievement of all of the criteria: UPCR <0.5 g/g; eGFR ≥85% of baseline, as calculated using the CKD-EPI equation. PRR was defined as achievement of all of the following criteria: ≥50% reduction in UPCR from baseline; UPCR <1 g/g (or <3 g/g if the baseline UPCR was ≥3 g/g); eGFR ≥85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Percentage have been rounded off.
Measured: At Week 50
Change From Baseline in Fatigue Assessed Using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
The FACIT-F is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-F score of 0 (worse score) to 52 (better score). Higher scores indicate less fatigue. Change in FACIT-F score from baseline at Week 76 was analyzed using ANCOVA model with covariates baseline FACIT-F score and the stratification factors race and region. Death was considered as an intercurrent event which was handled under composite strategy by imputing FACIT-F score after death with 0. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Measured: At Week 76
Change in Log-transformed Anti-double-stranded Deoxyribonucleic Acid (Anti-dsDNA) Titer
Anti-dsDNA are types of autoantibodies produced by the immune system and are indicators of lupus. Anti-dsDNA data was log-transformed before analysis. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with upper limit of quantification (ULOQ, 890 international units/milliliter [IU/mL]). Adjusted mean has been reported.
Measured: At Week 50
Change in Complement C3
C3 is a marker of inflammation. Analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with lower limit of quantification (LLOQ)/2 under composite strategy. LLOQ at the central lab was set for C3 at 0.100 grams/liters (g/L). Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Measured: At Week 50
Change in Systematic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
The SLEDAI-2K is a 24-item instrument that evaluates clinical symptoms and laboratory markers across nine organ systems and was used to capture changes in lupus-related disease activity. SLE manifestations are assessed by the clinician if present within the last 30 days and added to determine the total SLEDAI-2K score, which ranges from 0 to 105. Higher scores indicate increased disease activity. The analysis was performed using ANCOVA. Death was considered as an intercurrent event which was handled under composite strategy by imputing data after death with 105, the highest possible score. Missing data was imputed by multiple imputations using FCS predicted mean matching method. Adjusted mean has been reported.
Measured: At Week 76
Time to Onset of CRR
CRR was defined as an achievement of all the following criteria: UPCR <0.5 g/g; eGFR >=85% of baseline, as calculated using the CKD-EPI equation and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Participants who experienced the intercurrent events before achieving CRR as well as participants who completed 76-week treatment period without experiencing CRR were censored at Week 76. Summary statistics of time to onset of CRR are Kaplan-Meier estimates. A log-rank test was used to compare obinutuzumab and placebo. The median time to onset of CRR was greater than Week 76 due to considering the upper limit of the Week 76 analysis visit window in this analysis. The upper limit of the Week 76 visit window was 3 days prior to the next obinutuzumab or placebo infusion or 30 days beyond Week 76 whichever is shorter.
Measured: From baseline (Day 1) up to 80.3 weeks
Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria
CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR <0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by > 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.
Measured: At Week 76
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Measured: Up to Week 76
Number of Participants With Adverse Events of Special Interest (AESIs)
An AE was any untoward medical occurrence in participant administered a pharmaceutical product \& which does not necessarily have to have a causal relationship with treatment. It can therefore be any unfavorable \& unintended sign (including abnormal laboratory values/ abnormal clinical test results), symptoms, or disease temporally associated with use of pharmaceutical product, whether or not considered related to product. AESIs included potential drug-induced liver injury that include an elevated alanine transaminase (ALT) \& aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice defined by Hy's law; suspected transmission of an infectious agent by study drug; infusion-related reactions (IRRs); grade 3/higher infections; any hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML); drug-related neutropenia; drug-related thrombocytopenia; gastrointestinal perforations and worsening of pre-existing cardiac conditions
Measured: Up to Week 76
Number of Participants With Anti-Drug Antibodies (ADAs) Positive Post-Treatment
Determination of anti-obinutuzumab antibodies in serum samples were performed using a validated enzyme-linked Immunosorbent Assay (ELISA) method. Participants were considered to be ADA positive if they were ADA negative or have missing data at baseline but develop an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post baseline samples was at least ≥ 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
Measured: Up to approximately 11 years
Total Peripheral B-Cell (CD19) Count
Measured: Up to approximately 11 years
Concentration of Obinutuzumab in Serum
Measured: Up to approximately 11 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2020
- Study start10 Aug 2020
- Primary completion15 Aug 2024
- Study completion2 Mar 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Lupus NephritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 271 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04221477
- Sponsor's protocol ID
- CA41705
- Other IDs
- 2019-004034-42, 2023-503628-22-00, 2023, 2019
- Acronym
- REGENCY
- Status last verified
- Oct 2026
- First submitted
- 7 Jan 2020
- Last updated
- 19 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Publications
Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martinez G, Zuta Santillan AE, Alvarez D, Navarro Sandoval C, Lila AM, Tumlin JA, Saxena A, Irazoque Palazuelos F, Raghu H, Yoo B, Hassan I, Martins E, Sehgal H, Kirchner P, Ross Terres J, Omachi TA, Schindler T, Pendergraft WF 3rd, Malvar A; REGENCY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025 Apr 17;392(15):1471-1483. doi: 10.1056/NEJMoa2410965. Epub 2025 Feb 7.
PubMed 39927615Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.
PubMed 37528520Dossier C, Hogan J. Response to Majeranowski. Pediatr Nephrol. 2021 Jun;36(6):1653. doi: 10.1007/s00467-021-04982-4. Epub 2021 Mar 10. No abstract available.
PubMed 33693991